Brokerages Set Caris Life Sciences, Inc. (NASDAQ:CAI) Target Price at $27.56

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI) have been assigned an average rating of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $27.5556.

Several research firms have issued reports on CAI. JPMorgan Chase & Co. cut their target price on Caris Life Sciences from $35.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Citigroup cut their target price on Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, May 8th. The Goldman Sachs Group began coverage on Caris Life Sciences in a research note on Wednesday, April 1st. They set a “buy” rating and a $27.00 target price for the company. BTIG Research cut their target price on Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen cut Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd.

Insider Transactions at Caris Life Sciences

In other Caris Life Sciences news, Director Jeff L. Vacirca bought 31,050 shares of the business’s stock in a transaction on Monday, May 11th. The stock was bought at an average price of $16.15 per share, with a total value of $501,457.50. Following the completion of the purchase, the director directly owned 49,671 shares in the company, valued at $802,186.65. The trade was a 166.75% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CAI. Diversified Trust Co. purchased a new position in shares of Caris Life Sciences during the fourth quarter worth $540,000. Olistico Wealth LLC purchased a new position in shares of Caris Life Sciences during the fourth quarter worth $31,000. Zevenbergen Capital Investments LLC purchased a new position in shares of Caris Life Sciences during the fourth quarter worth $14,655,000. Hamilton Lane Advisors LLC purchased a new position in shares of Caris Life Sciences during the fourth quarter worth $1,584,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Caris Life Sciences by 26.5% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 75,330 shares of the company’s stock worth $2,032,000 after buying an additional 15,778 shares during the period.

Caris Life Sciences Stock Performance

NASDAQ:CAI opened at $15.38 on Thursday. Caris Life Sciences has a one year low of $14.19 and a one year high of $42.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 6.52 and a current ratio of 7.05. The firm has a market capitalization of $4.35 billion and a PE ratio of -2.02. The firm has a 50 day moving average of $18.16.

Caris Life Sciences (NASDAQ:CAI) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.01 by $0.27. The firm had revenue of $292.89 million during the quarter, compared to analysts’ expectations of $281.00 million. Caris Life Sciences had a return on equity of 98.28% and a net margin of 3.75%.The business’s revenue for the quarter was up 125.4% on a year-over-year basis. During the same quarter last year, the firm earned ($1.73) earnings per share. As a group, analysts predict that Caris Life Sciences will post 0.1 earnings per share for the current fiscal year.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.